Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,412JPY
2 Dec 2016
Change (% chg)

¥-18 (-0.74%)
Prev Close
¥2,430
Open
¥2,430
Day's High
¥2,432
Day's Low
¥2,402
Volume
2,684,200
Avg. Vol
2,465,256
52-wk High
¥2,750
52-wk Low
¥2,078

Latest Key Developments (Source: Significant Developments)

Daiichi Sankyo Lixiana receives positive CHMP opinion in Europe
Sunday, 26 Apr 2015 08:00pm EDT 

Daiichi Sankyo Co Ltd:The European Committee for Medicinal Products for Human Use recommended approval of once-daily Lixiana.And says once-daily Lixiana receives positive CHMP opinion for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation and for the treatment and prevention of recurrent venous thromboembolism.Daiichi Sankyo looks forward to receiving approval decision by the European Commission soon, which is the basis for marketing authorisation in all European Union member states.  Full Article

Daiichi Sankyo sells stake in Sun Pharmaceutical Industries
Tuesday, 21 Apr 2015 01:45am EDT 

Daiichi Sankyo Co Ltd:Completed to sell 214,969,058 shares of India-based company Sun Pharmaceutical Industries Ltd on April 21.Holds 0 share of Sun Pharmaceutical Industries at present.  Full Article

Daiichi Sankyo to sell shares of Sun Pharmaceutical Industries Ltd
Monday, 20 Apr 2015 07:15am EDT 

Daiichi Sankyo Co Ltd:To sell entire or part of shares of India-based company Sun Pharmaceutical Industries Ltd.The company is holding 214,969,058 shares of Sun Pharmaceutical Industries.  Full Article

Daiichi Sankyo Co Ltd and Asubio Pharmaceuticals Inc merge
Wednesday, 1 Apr 2015 08:00am EDT 

Daiichi Sankyo Co Ltd:Says it will merge with its US-based sister company, Asubio Pharmaceuticals Inc.Says Asubio Pharmaceuticals' parent company, Asubio Pharma Co., Ltd, which is based in Japan, will continue to operate as wholly owned subsidiary of Daiichi Sankyo Co Ltd with focus on discovery research.  Full Article

Sun Pharmaceutical Industries acquires stake in Ranbaxy Laboratories from Daiichi Sankyo
Wednesday, 25 Mar 2015 02:30am EDT 

Daiichi Sankyo Co Ltd:Sun Pharmaceutical Industries Ltd completed acquisition of stake in Ranbaxy Laboratories, which was a 63.4 pct-owned subsidiary of Daiichi Sankyo, through stock swap, on March 24.Plan disclosed on April 7, 2014.  Full Article

Daiichi Sankyo subsidiary signs co-commercialization agreement with AstraZeneca
Thursday, 19 Mar 2015 03:00am EDT 

Daiichi Sankyo Co Ltd:An U.S-based subsidiary signed a co-commercialization agreement of MOVANTIK (generic name naloxegol) in U.S with a London-based company named AstraZeneca.MOVANTIK is a narcotic analgesic for treatment of induced constipation.  Full Article

Daiichi Sankyo announces civil settlement of U.S-based subsidiary
Monday, 12 Jan 2015 06:30pm EST 

Daiichi Sankyo Co Ltd:U.S-based subsidiary Daiichi Sankyo, Inc. announced that it has reached a civil settlement with the U.S. Government, as well as participating states to conclude a Federal investigation related to certain types of speaker programs related to Azor, Benicar, Benicar HCT, Welchol and Tribenzor.Under the agreement, the U.S-based subsidiary has agreed to pay approximately $39 million, plus fees and costs, and has entered into a Corporate Integrity Agreement with the Office of Inspector General for the U.S. Department of Health and Human Services.  Full Article

Daiichi Sankyo subsidiary gets FDA approval
Thursday, 8 Jan 2015 07:15pm EST 

Daiichi Sankyo Co Ltd:Says U.S.-based subsidiary received approval for its investigational, oral, once-daily direct factor Xa-inhibitor SAVAYSATM (edoxaban) Tablets from the U.S. Food and Drug Administration (FDA), in U.S. on Jan. 8.Approval for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF), as well as for the treatment of venous thromboembolism.  Full Article

BRIEF-Portola Pharmaceuticals expands pact with Daiichi Sankyo

* Portola Pharmaceuticals expands clinical collaboration agreement with Daiichi Sankyo worth up to $25 million to develop ANDEXXA (Andexanet Alfa) in Germany